China's Luye Pharma Group wants to step up its game–and some of its key investors want to cash out. So, it's planning an initial public offering in Hong Kong worth up to HK$5.9 billion, or about $761 million.
written on 23.06.2014
Chinese drugmaker plots $761M stock offering to fund deals, R&D
